238 related articles for article (PubMed ID: 32845521)
1. Databases for the targeted COVID-19 therapeutics.
Wang Y; Li F; Zhang Y; Zhou Y; Tan Y; Chen Y; Zhu F
Br J Pharmacol; 2020 Nov; 177(21):4999-5001. PubMed ID: 32845521
[No Abstract] [Full Text] [Related]
2. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
Wang Y; Chen L
Br J Pharmacol; 2020 Nov; 177(21):4995-4996. PubMed ID: 32424836
[No Abstract] [Full Text] [Related]
3. Boosting the arsenal against COVID-19 through computational drug repurposing.
Ciliberto G; Cardone L
Drug Discov Today; 2020 Jun; 25(6):946-948. PubMed ID: 32304645
[No Abstract] [Full Text] [Related]
4. East meets West in COVID-19 therapeutics.
Wang S; Zeng X; Wang Y; Zhao Y; Chen W; Chen YZ
Pharmacol Res; 2020 Sep; 159():105008. PubMed ID: 32531323
[No Abstract] [Full Text] [Related]
5. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.
Taccone FS; Gorham J; Vincent JL
Lancet Respir Med; 2020 Jun; 8(6):539-541. PubMed ID: 32304640
[No Abstract] [Full Text] [Related]
7. The potential role of nanomedicine on COVID-19 therapeutics.
Mainardes RM; Diedrich C
Ther Deliv; 2020 Jul; 11(7):411-414. PubMed ID: 32594863
[No Abstract] [Full Text] [Related]
8. Fight against novel coronavirus: A perspective of medicinal chemists.
Amin SA; Jha T
Eur J Med Chem; 2020 Sep; 201():112559. PubMed ID: 32563814
[TBL] [Abstract][Full Text] [Related]
9. BET 2: Hydroxychloroquine in the treatment of COVID-19.
Howard L; Baombe J; Reynard C
Emerg Med J; 2020 Jul; 37(7):451-453. PubMed ID: 32616659
[No Abstract] [Full Text] [Related]
10. Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19.
Fassihi SC; Nabar NR; Fassihi R
Br J Pharmacol; 2020 Nov; 177(21):4997-4998. PubMed ID: 32562278
[No Abstract] [Full Text] [Related]
11. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
12. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.
Alexander SPH; Armstrong JF; Davenport AP; Davies JA; Faccenda E; Harding SD; Levi-Schaffer F; Maguire JJ; Pawson AJ; Southan C; Spedding M
Br J Pharmacol; 2020 Nov; 177(21):4942-4966. PubMed ID: 32358833
[TBL] [Abstract][Full Text] [Related]
13. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
Severa M; Farina C; Salvetti M; Coccia EM
Front Immunol; 2020; 11():1459. PubMed ID: 32655578
[No Abstract] [Full Text] [Related]
14. COVID-19: A Defining Moment for Clinical Pharmacology?
van der Graaf PH; Giacomini KM
Clin Pharmacol Ther; 2020 Jul; 108(1):11-15. PubMed ID: 32350861
[No Abstract] [Full Text] [Related]
15. Discovering small-molecule therapeutics against SARS-CoV-2.
Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR
Drug Discov Today; 2020 Aug; 25(8):1535-1544. PubMed ID: 32574699
[TBL] [Abstract][Full Text] [Related]
16. Combating devastating COVID-19 by drug repurposing.
Pawar AY
Int J Antimicrob Agents; 2020 Aug; 56(2):105984. PubMed ID: 32305589
[TBL] [Abstract][Full Text] [Related]
17. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery.
Senger MR; Evangelista TCS; Dantas RF; Santana MVDS; Gonçalves LCS; de Souza Neto LR; Ferreira SB; Silva-Junior FP
Mem Inst Oswaldo Cruz; 2020; 115():e200254. PubMed ID: 33027420
[TBL] [Abstract][Full Text] [Related]
18. Drug repurposing in the era of COVID-19: a call for leadership and government investment.
Martin JH; Bowden NA
Med J Aust; 2020 Jun; 212(10):450-452.e1. PubMed ID: 32372435
[No Abstract] [Full Text] [Related]
19. Dexamethasone nanomedicines for COVID-19.
Lammers T; Sofias AM; van der Meel R; Schiffelers R; Storm G; Tacke F; Koschmieder S; Brümmendorf TH; Kiessling F; Metselaar JM
Nat Nanotechnol; 2020 Aug; 15(8):622-624. PubMed ID: 32747742
[No Abstract] [Full Text] [Related]
20. Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2.
Wamae CN
Am J Trop Med Hyg; 2020 Jul; 103(1):10-11. PubMed ID: 32458795
[No Abstract] [Full Text] [Related]
[Next] [New Search]
